JP2019517498A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517498A5 JP2019517498A5 JP2018562918A JP2018562918A JP2019517498A5 JP 2019517498 A5 JP2019517498 A5 JP 2019517498A5 JP 2018562918 A JP2018562918 A JP 2018562918A JP 2018562918 A JP2018562918 A JP 2018562918A JP 2019517498 A5 JP2019517498 A5 JP 2019517498A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- weeks
- ctla
- administered
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 11
- 230000037396 body weight Effects 0.000 claims 10
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 8
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 8
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 4
- 229960003301 nivolumab Drugs 0.000 claims 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- 208000000649 small cell carcinoma Diseases 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 230000000118 anti-neoplastic effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003124 biologic agent Substances 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 102000043321 human CTLA4 Human genes 0.000 claims 1
- 102000048362 human PDCD1 Human genes 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229950007221 nedaplatin Drugs 0.000 claims 1
- 190000005734 nedaplatin Chemical compound 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- -1 phenanthriplatin Chemical compound 0.000 claims 1
- 229950005566 picoplatin Drugs 0.000 claims 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 229960005399 satraplatin Drugs 0.000 claims 1
- 190014017285 satraplatin Chemical compound 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
- 229950002860 triplatin tetranitrate Drugs 0.000 claims 1
- 190014017283 triplatin tetranitrate Chemical compound 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022007372A JP2022058699A (ja) | 2016-06-03 | 2022-01-20 | 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体 |
| JP2024141986A JP2024167282A (ja) | 2016-06-03 | 2024-08-23 | 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345463P | 2016-06-03 | 2016-06-03 | |
| US62/345,463 | 2016-06-03 | ||
| PCT/US2017/035808 WO2017210631A1 (en) | 2016-06-03 | 2017-06-02 | Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022007372A Division JP2022058699A (ja) | 2016-06-03 | 2022-01-20 | 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019517498A JP2019517498A (ja) | 2019-06-24 |
| JP2019517498A5 true JP2019517498A5 (enExample) | 2020-07-09 |
Family
ID=59054317
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562918A Pending JP2019517498A (ja) | 2016-06-03 | 2017-06-02 | 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ−１抗体 |
| JP2022007372A Pending JP2022058699A (ja) | 2016-06-03 | 2022-01-20 | 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体 |
| JP2024141986A Pending JP2024167282A (ja) | 2016-06-03 | 2024-08-23 | 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022007372A Pending JP2022058699A (ja) | 2016-06-03 | 2022-01-20 | 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体 |
| JP2024141986A Pending JP2024167282A (ja) | 2016-06-03 | 2024-08-23 | 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20190292260A1 (enExample) |
| EP (2) | EP4386005A3 (enExample) |
| JP (3) | JP2019517498A (enExample) |
| KR (1) | KR20190015407A (enExample) |
| CN (1) | CN109475634A (enExample) |
| WO (1) | WO2017210631A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9856320B2 (en) * | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| HRP20201334T1 (hr) * | 2015-04-17 | 2020-11-27 | Bristol-Myers Squibb Company | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| US11072657B2 (en) | 2015-11-18 | 2021-07-27 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody |
| WO2017210631A1 (en) | 2016-06-03 | 2017-12-07 | Bristol-Myers Squibb Company | Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer |
| IL307242B1 (en) | 2016-12-07 | 2026-07-01 | Agenus Inc | Anti-CTLA-4 antibodies and methods of using them |
| EP3774911A1 (en) * | 2018-03-30 | 2021-02-17 | Bristol-Myers Squibb Company | Methods of treating tumor |
| WO2020081783A2 (en) * | 2018-10-18 | 2020-04-23 | Medimmune, Llc | Anti-ox40, anti-pd-l1 and anti-ctla-4 antibodies for treating tumors |
| JP2022505647A (ja) * | 2018-10-23 | 2022-01-14 | ブリストル－マイヤーズ スクイブ カンパニー | 腫瘍の処置方法 |
| KR20210146348A (ko) * | 2019-03-28 | 2021-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| AR122043A1 (es) * | 2020-05-12 | 2022-08-03 | Bristol Myers Squibb Co | Dosificación y administración del anticuerpo anti-ctla-4 activable |
| CA3196496A1 (en) | 2020-10-23 | 2022-04-28 | Laurence David TOMS | Lag-3 antagonist therapy for lung cancer |
| US20240050564A1 (en) * | 2021-01-08 | 2024-02-15 | Bristol-Myers Squibb Company | Combination therapy using an anti-fucosyl-gm1 antibody |
| TW202602492A (zh) * | 2024-04-05 | 2026-01-16 | 瑞典商阿斯特捷利康公司 | 局限期小細胞肺癌之治療 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| AU2001233027A1 (en) | 2000-01-27 | 2001-08-07 | Genetics Institute, Llc | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| ES2699965T3 (es) | 2011-03-10 | 2019-02-13 | Provectus Pharmatech Inc | Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| HUE054012T2 (hu) | 2014-10-29 | 2021-08-30 | Five Prime Therapeutics Inc | Kombinációs terápia rák ellen |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| WO2017210631A1 (en) | 2016-06-03 | 2017-12-07 | Bristol-Myers Squibb Company | Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer |
-
2017
- 2017-06-02 WO PCT/US2017/035808 patent/WO2017210631A1/en not_active Ceased
- 2017-06-02 KR KR1020187038117A patent/KR20190015407A/ko not_active Ceased
- 2017-06-02 JP JP2018562918A patent/JP2019517498A/ja active Pending
- 2017-06-02 CN CN201780048326.3A patent/CN109475634A/zh active Pending
- 2017-06-02 EP EP24158972.0A patent/EP4386005A3/en active Pending
- 2017-06-02 US US16/306,383 patent/US20190292260A1/en not_active Abandoned
- 2017-06-02 EP EP17729720.7A patent/EP3463454A1/en not_active Withdrawn
-
2021
- 2021-07-08 US US17/370,791 patent/US11767361B2/en active Active
-
2022
- 2022-01-20 JP JP2022007372A patent/JP2022058699A/ja active Pending
-
2023
- 2023-08-15 US US18/450,219 patent/US20240052035A1/en active Pending
-
2024
- 2024-08-23 JP JP2024141986A patent/JP2024167282A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019503387A5 (enExample) | ||
| RU2016148927A (ru) | Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства | |
| US12116363B2 (en) | Combinations for immune-modulation in cancer treatment | |
| JP2019517511A5 (enExample) | ||
| JP2019516711A5 (enExample) | ||
| JP2022533578A5 (enExample) | ||
| JP2016520082A5 (enExample) | ||
| JP2019517505A5 (enExample) | ||
| JP2023526259A5 (enExample) | ||
| Karayama et al. | Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study | |
| US20090196871A1 (en) | Use of 4-pyridylmethylphthalazines for cancer treatment | |
| Kubota et al. | Feasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and dexamethasone for docetaxel-refractory prostate cancer | |
| AU2015242786B2 (en) | Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
| JP7168575B2 (ja) | トリフルリジン／チピラシル塩酸塩、抗腫瘍白金錯体、及び免疫チェックポイント調節剤の新規組み合わせ物 | |
| Clark et al. | Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer | |
| AU2002342678A1 (en) | Use of 4-pyridylmethylphthalazines for cancer treatment | |
| Barroso-Sousa et al. | The Clinical Development of Immune Checkpoint Inhibitors in Combination with Targeted Therapy in Breast Cancer | |
| Seliger et al. | Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum-and paclitaxel-pretreated epithelial ovarian cancer | |
| EP1712234A1 (en) | Use of 4-Pyridylmethylphthalazines for Cancer Treatment | |
| HK40015395A (en) | Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator | |
| Trédaniel et al. | An open phase II trial of gemcitabine, oxaliplatin and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patients | |
| NZ552119A (en) | Use of a 4-pyridylmethylphthalazines for renal cancer treatment | |
| ZA200401184B (en) | Use of 4-pyridylmethylphthalazines for cancer treatment. |